The use of voriconazole in the treatment of Aspergillus fumigatus keratitis.
作者信息
Stewart Rosalind M K, Quah Say Aun, Neal Timothy J, Kaye Stephen B
出版信息
Br J Ophthalmol. 2007 Aug;91(8):1094-6. doi: 10.1136/bjo.2006.111989.
Abstract
摘要
相似文献
1
The use of voriconazole in the treatment of Aspergillus fumigatus keratitis.
Br J Ophthalmol. 2007 Aug;91(8):1094-6. doi: 10.1136/bjo.2006.111989.
2
Aspergillus fumigatus-related spondylodiscitis in a heart transplant patient successfully treated with voriconazole.
Transplant Proc. 2007 Oct;39(8):2627-8. doi: 10.1016/j.transproceed.2007.08.014.
3
Lack of efficacy of voriconazole therapy in 2 patients with pulmonary fungus balls.
Clin Infect Dis. 2005 Jun 1;40(11):1706-7. doi: 10.1086/430176.
4
Aspergillus osteomyelitis: review of 12 cases identified by the Prospective Antifungal Therapy Alliance registry.
Diagn Microbiol Infect Dis. 2009 Apr;63(4):384-7. doi: 10.1016/j.diagmicrobio.2008.12.005. Epub 2009 Feb 26.
5
Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases.
Transplant Proc. 2004 Nov;36(9):2708-9. doi: 10.1016/j.transproceed.2004.09.043.
6
Multiple-triazole-resistant aspergillosis.
N Engl J Med. 2007 Apr 5;356(14):1481-3. doi: 10.1056/NEJMc061720.
7
Voriconazole for the treatment of refractory Aspergillus fumigatus keratitis.
Indian J Ophthalmol. 2008 May-Jun;56(3):243-5. doi: 10.4103/0301-4738.40369.
8
Aspergillus flavus keratomycosis in a cat treated with topical 1% voriconazole solution.
Vet Ophthalmol. 2009 Jan-Feb;12(1):48-52. doi: 10.1111/j.1463-5224.2009.00673.x.
9
Natamycin and voriconazole in Fusarium and Aspergillus keratitis: subgroup analysis of a randomised controlled trial.
Br J Ophthalmol. 2012 Nov;96(11):1440-1. doi: 10.1136/bjophthalmol-2012-301825. Epub 2012 Aug 21.
10
Aspergillus fumigatus spondylodiskitis in renal transplant patient: voriconazole experience.
Exp Clin Transplant. 2011 Aug;9(4):265-9.
引用本文的文献
1
Aspergillus fumigatus scleritis associated with monoclonal gammopathy of undetermined significance.
Korean J Ophthalmol. 2010 Jun;24(3):175-8. doi: 10.3341/kjo.2010.24.3.175. Epub 2010 Jun 5.
本文引用的文献
1
Risk factors for treatment outcome in fungal keratitis.
Ophthalmology. 2006 Apr;113(4):526-30. doi: 10.1016/j.ophtha.2005.10.063.
2
Topical voriconazole as a novel treatment for fungal keratitis.
Antimicrob Agents Chemother. 2006 Jan;50(1):262-8. doi: 10.1128/AAC.50.1.262-268.2006.
3
Voriconazole in the management of Alternaria keratitis.
Cornea. 2006 Feb;25(2):242-4. doi: 10.1097/01.ico.0000170692.05703.98.
4
Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole.
Clin Infect Dis. 2005 Jun 15;40(12):e110-2. doi: 10.1086/430062. Epub 2005 May 12.
5
In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
Am J Ophthalmol. 2004 May;137(5):820-5. doi: 10.1016/j.ajo.2003.11.078.
6
Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.
Arch Ophthalmol. 2004 Jan;122(1):42-7. doi: 10.1001/archopht.122.1.42.
7
Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole.
J Clin Microbiol. 2003 May;41(5):2261-4. doi: 10.1128/JCM.41.5.2261-2264.2003.
8
Voriconazole: in the treatment of invasive aspergillosis.
Drugs. 2002;62(18):2655-64; discussion 2665-6. doi: 10.2165/00003495-200262180-00010.
9
Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole.
Br J Ophthalmol. 2000 Aug;84(8):932-3. doi: 10.1136/bjo.84.8.928d.
Zotero 插件